
==== Front
One Health
One Health
One Health
2352-7714
Elsevier

S2352-7714(24)00197-6
10.1016/j.onehlt.2024.100871
100871
Short Communication
One Health policy for combatting African trypanocide resistance
Kasozi Keneth Iceland Keneth.kasozi@ed.ac.uk
ab⁎
MacLeod Ewan Thomas a
Welburn Susan Christina sue.welburn@ed.ac.uk
acde⁎
a Infection Medicine, Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, United Kingdom
b School of Medicine, Kabale University, Kabale University, Box 317, Kabale, Uganda
c Key Laboratory of Tropical Translational Medicine of Ministry of Education, The School of Tropical Medicine, The First Affiliated Hospital, Hainan Medical University, Haikou 571199, Hainan, People's Republic of China
d School of Global Health, Chinese Centre for Global Tropical Disease Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China
e Zhejiang University - University of Edinburgh Joint Institute, Zhejiang University, International Campus, 718 East Haizhou Road, Haining 314400, People's Republic of China
⁎ Corresponding authors at: Infection Medicine, Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, United Kingdom. Keneth.kasozi@ed.ac.uksue.welburn@ed.ac.uk
05 8 2024
12 2024
05 8 2024
19 10087110 6 2024
29 7 2024
2 8 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
The rise of African trypanocide resistance (ATr) is influenced by various factors such as evolutionary changes in the pathogen, the presence of resistance genes in the population, poor policy decisions, limited private-public partnerships to engage local communities, and insufficient funding for the development of new drugs over the past sixty years. These challenges have been exacerbated by the inadequate implementation of drug liberalization policies in the mid 20th century, leading to poor pharmacovigilance practices for veterinary drugs in low and middle income countries (LMICs). One health (OH), a disease management framework, provides practical solutions for addressing ATr, drawing on its success in managing previous epidemics like avian influenza in 2004 and the recent COVID-19 pandemic, where institutional collaborations were rapidly established. To combat ATr, OH initiatives involving both international and local partners at the policy and grassroots levels are crucial to generate community interest. The importance of political commitment, media involvement, and nongovernmental organizations cannot be overstated, as they are essential for resource mobilization and long-term sustainability in LMICs.

Keywords

Neglected tropical diseases
One Health
COVID-19
Trypanosomiasis
Developing countries
Global health
Funding
Infectious diseases
==== Body
pmc1 Introduction

There is increasing scientific evidence for the evolution of antimicrobial drug resistance (AMR) to the drugs available to treat human African trypanosomes (HAT) and animal African trypanosomiasis (AAT) [1,2]. In most rural communities, inappropriate use of trypanocides is considered to confer selection pressure for resistance genes to develop in trypanosome populations [3]. The emergence of drug resistance phenotypes has complicated both control AAT and impeded progress towards the elimination of HAT as a public health problem by 2030 [4,5]. Drug resistant trypanosomes have been found in humans [6], livestock [7] and the tsetse fly insect vector [8] and this is a key concern due to weak regulatory policies contributing to the growing antimicrobial resistance (AMR) in endemic countries. Given the emergence of drug resistance and lack of new trypanocides in development for AAT, the use of chemotherapy alone as a primary method to control AAT in sub–Saharan Africa is no longer a sustainable approach [9].

The fear of influenza pandemics was instrumental in galvanizing international attention and collaborative efforts which led to the birth of one-health (OH). The global anxiety surrounding the highly pathogenic avian influenza (HPAI) subtype H5N1, commonly known as bird flu in 2004 was driven by its high mortality rate in poultry and the potential for the virus to mutate and spread to humans, causing a severe and widespread outbreak [10]. This provided an opportunity to unify the Food and Agriculture Organization (FAO), World Organization for Animal Health (WOAH), World Health Organization (WHO) and the World Bank and develop comprehensive strategies to address emerging zoonotic diseases [11,12]. By fostering collaborations, these agencies pool their expertise and resources to develop more effective strategies to address zoonotic diseases. Interdisciplinary collaborations bring together experts from various fields, including veterinarians, epidemiologists, environmental scientists, public health professionals, and economists. This creates a complex web while developing comprehensive solutions. Furthermore, international, and national authorities having equal partnership demonstrates a need for a strong leadership platform. The threat of HPAI H5N1 did recede (A. L. [13]), however, COVID-19 demonstrated the importance of having a strong operational OH policy in place [14]. Furthermore, OH in rabies control has been associated with a drop in the number of cases and helped veterinarians gain more confidence in handling cases, reduced production costs and increased sharing of information between veterinarians and medical sectors [15], despite the limited rabies surveillance systems which are scarce in Africa [16]. In Latin America, the commitment and engagement of the health sector have been pivotal in integrating rabies control into broader national rabies control programs. This integration has significantly contributed to the successful implementation of OH principles in the region [17]. COVID-19 exposed the dysconnectivity between governmental promotion of OH and the reality outside of governmental agencies [18,19]. OH creates a platform for leadership and knowledge sharing, as exemplified by the Canadian OH platform which has members from the political sciences, sociology, law, economics, anthropology, veterinary, human health, public health, environmental sciences, epidemiology and implantation research [20]. In line with the WHO post COVID-19 preparedness plan for the next pandemic (Tedros [21]), OH offers a feasible platform to address the growing African trypanocide resistance challenge on the African continent. In essence, by addressing diseases in animal populations, we not only protect the health and welfare of animals but also contribute to the broader goals of ecosystem health, biodiversity conservation, and sustainable resource management. This holistic approach is crucial for maintaining healthy and resilient ecosystems in the face of global challenges.

1.1 Liberalization of the African trypanocide industry

Demands to open the African market/industry for drug manufacture and supply have led to the establishment of local manufacturing pharmaceutical companies with linkages to multinational European counterparts. Severe economic pressures and declining manufacturing in the late 1970s were associated with the birth of the liberalization policy which included the pharmaceutical industry in several African countries [22]. For effective prevention of AMR development, national regulatory frameworks are required, ideally established by thorough intergovernmental collaborations on OH. These help develop and promote good manufacturing practice (GMP) regulations regionally and enable harmonized monitoring strategies [23]; GMP remains a significant challenge in most low and middle income countries (LIMICs) and the requirement for more active collaboration in drug monitoring and guidance in both human and animal health ministries is long overdue. The World Trade Organization (WTO), WHO, and WOAH are all committed to collaborate more closely to create better infection control strategies [24], but too often communication channels operating at the ministerial level are not translated to grassroot administrative units, making it challenging to implement OH messaging and good practice in these communities.

To address HAT resistance (HATr), collaborative international partners have supported biomedical research into novel therapies such as nifurtimox/eflornithine combinations. Drugs have been repurposed and clinical trials are in advanced stages. In contrast, resources for new drug options for AAT resistance (AATr) are lacking, arising from disproportionate allocation of funding in the WHO/WOAH related biomedical and clinical research [25]. This situation has been worsened further during the COVID-19 pandemic where disproportionate funding has seen increased poverty and marginalization for the control of NTDs in LMICs [26]. Ignoring investment in new drugs and appropriate existing drug use in livestock poses a significant risk to human and animal health, and this is very important in LMICs where veterinary policy is weak (A. L. [27]). The WHO 2021–2030 road map has been updated for the elimination of HAT and AAT as a public health problem [28] which is an update from the previous target were gHAT was a target for transmission alone [4]. This implied WHO prioritized (gambiense) gHAT over (rhodesiense) rHAT (see [29] where new drugs for gHAT are elaborated) and with these new developments, it is apparent Trypanosoma brucei species are now a priority. Attempting to control a zoonotic infection without long-term management of infection in reservoir species is unlikely to be successful. Chronic failures to address AATr also contribute to human spillover infections (HATr) [3]. AATr control is complicated by the weak veterinary policies (poor surveillance, diagnostics and political commitment) in endemic communities [30,31], where net migration (re-stocking and livestock trade) contributes to the re-introduction of infections in human populations (A. L. [27,32]). There was already a funding crisis for tackling neglected tropical diseases (NTDs) [33,34,35], exacerbated by the impacts of COVID-19 and the difficult decisions that needed to be made in the allocation of budgets. Given that some NTDs are widening their range as a result of climate change, travel and trade [36], and considering lessons learned from the COVID-19 pandemic [37], a lack of investment will stifle the WHO/FAO trypanosomiasis elimination target. Taking a more holistic OH approach to infection control can reap significant benefits (A. [38]). For example, OH in East Africa (Uganda) in the control of emerging and re-emerging zoonotic infections i.e., Ebola, Marburg, plague, avian influenza, Rift valley fever, anthrax and yellow fever [39] as well as NTDs, especially on HAT [40] and the strengthening of national laboratories to detect zoonotic infections [41] do provide evidence for the benefits of multidisciplinary-sectoral collaborations. A comprehensive list of successful stories for the control of NTDs through an integration of OH [42] generates momentum for the adoption of OH for the management of ATr in the post pandemic age.

1.2 African trypanocide therapeutics in the COVID-19 age

The Stamp Out Sleeping Sickness (SOS) campaign [43], in Uganda whereby insecticides combined with trypanocides administered in cattle contributed to the reduction of the HAT burden is a classical example were OH has been successful. SOS involved multidisciplinary international collaborative initiative for the control of an NTD in Eastern Africa. Despite challenges associated with the implementation of OH as exemplified through the SOS project under the Coordinating Office for Control of Trypanosomiasis in Uganda (COCTU) such as leadership, ownership, and limited long-term financial support which demonstrated the importance of financial resource allocation to resolve conflicts (A. L. [44]), the COCTU secretariat did receive political endorsement and local support thus making COCTU one of the most successful global OH bodies now being reabsorbed into the Ministry of Health (Uganda) in the post-pandemic era. Another successful case study where OH has been successful involved the rabies campaign in developing countries. In Tanzania during the rabies elimination project funded under the Bill and Melinda Gates Foundation, engagement with several key ministries and the Prime Minister's Office helped to generate momentum for project ownership despite infrastructure challenges due to cold chain for vaccine handling, and road access (A. L. [44]). This provides evidence that OH remains relevant today to address AMR in Neglected Tropical Diseases (NTDs) including challenges of counterfeits that are proliferative in most developing countries.

Inadequate, excessive or substandard antimicrobial drugs contribute to treatment failures, allowing infections to persist and potentially become resistant to available treatments [45]. This situation poses a grave threat to public health, especially in regions where access to quality healthcare and effective medications is already limited [46]. However, across rural communities in sub-Saharan Africa, farmers continue to buy substandard and unregulated trypanocides, for use in their animals, many not licenced in the market into which they are being sold [47] simply because they are cheap, and do not observe safe practice withdrawal periods prior to selling their animal given there is no monitoring in place [48]. From the community perspective, it is inevitable that a smallholder farmer in the absence of professional advice will opt for cheap drugs regardless of quality, but farmer-based treatments characterized by poor dosing, and failure to observe withdrawal periods do raise major public health risks as well as major animal welfare concerns. Concerns as to drug administration by farmers are not limited to trypanocides, and in countries with poor veterinary and human drug regulatory policies, as is common in the global south, lax regulations, infrastructure challenges, and a chronic lack of legal oversight create an environment where AMR can develop, unimpeded. Adoption of a holistic OH approach to combat AMR provides real opportunities for national governments with these infrastructure challenges to maximize the available human resources [49].

The interconnectedness of health as demonstrated by the COVID-19 pandemic and its consequences justifies the social and economic benefits of amalgamating professionals to work under one administrative framework. Unfortunately, while informal memorandums of collaborations between institutions have been written in line with WHO recommendations [50], the adoption of OH has rarely been mainstreamed into Government policy. A multitude of resources have been made available by the WHO to support and guide nations for the institutionalization of OH. Furthermore, WHO has encouraged LMICs to develop collaborative initiatives in preparation for the next pandemic. Most high-income countries (HICs) e.g., USA and UK have developed their response plans as was observed during the early phases of the pandemic [51,52], however, LMICs are at risk of being left behind. Individualism among nations works contrary to the United Nations (UN) Collective Action Plan, however, the political atmosphere in UN member states is responsible for these divergent policy decisions which work against efforts to promote planetary health for the control of epidemics.

The success of the COVID-19 response was, in part, due to strong political leadership and coordinated efforts at various levels of government and international bodies. This was especially important to counteract strange conspiracy theories and denialism (see [53] in the UK, Ireland, Spain, USA and Mexico) thus helping bring diverse perspectives from politics, funders, healthcare and policymaking under one framework [54]. For AMR and NTDs, similar political commitment is crucial. Governments need to prioritize these issues, allocate resources, and support international collaborations. The media played a pivotal role in framing COVID-19 as a pressing global crisis, which drove public engagement and compliance with health measures [55]. To address AMR and NTDs, it is essential to harness media and communication strategies to raise awareness, educate the public, and advocate for urgent action. The pandemic showed the importance of global cooperation. For diseases affecting LMICs, creating and maintaining strong international partnerships among governments, non-governmental organizations, and private sectors can enhance resource mobilization, research, and intervention efforts.

The private sector played a role in developing COVID-19 vaccines and treatments [56], its involvement is critical in the fight against ATr. Engaging pharmaceutical companies, biotech firms, and other private entities can drive innovation and ensure the availability of effective treatments and diagnostics. The Bill and Melinda Gates Foundation through GALVmed approved over USD 19 million for phase 3 trials for new drugs against AAT [57], and more recently collaborations between GALVmed, the UK Government Foreign Commonwealth and Development Office, Boehringer Ingelheim and GALVmed have made a concerted effort to combat ATr [58]. Unfortunately, reciprocal collaborations at the grassroot movements involving LMIC institutions and the government remain scarce. This implies media mobilization to advocate for ATr control at the community level, though crucial remains elusive. Empowering local organizations and communities to participate in and lead health initiatives can improve the effectiveness and sustainability of ATr interventions.

2 Conclusion

Although the WHO, WOAH, WTO, FAO work together, oversight of OH activities remains idealistic especially at the national level. Individualism, protectionism, duplication of research, and corruption as well as a lack of a streamlined leadership framework are major barriers to the realization of the OH strategy for infection control. To improve institutional preparedness in developing countries in anticipation of the perfect pathogen (Pathogen X = infectious like COVID-19, and virulent like Ebola), WHO has promoted OH to reduce spillover events. Without clear national and regional policies on OH, this objective will remain elusory in both HICs and LMICs. A coordinated approach that integrates political will, media engagement, global collaboration, private sector involvement, and grassroots mobilization is essential for addressing ATr effectively. By learning from the COVID-19 response, stakeholders can work together to create a powerful, united front against African trypanosomiasis in LMICs.

Author disclaimer

The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Ethical approval statement

Not applicable.

Funding source

This research was supported by the 10.13039/501100000272 National Institute for Health Research (16/136/33) using United Kingdom aid from the United Kingdom Government (SCW). This work was also supported by 10.13039/501100004835 Zhejiang University Research Fund (SCW) and funded by the 10.13039/501100000867 Commonwealth Scholarship Commission (UGSC–2021–447 ) in the United Kingdom and the Small Grants Programme of the 10.13039/501100000683 Royal Society of Tropical Medicine and Hygiene (2021) in partnership with the 10.13039/501100000272 National Institute for Health Research (NIHR) (KIK).

CRediT authorship contribution statement

Keneth Iceland Kasozi: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Resources, Methodology, Investigation, Funding acquisition, Conceptualization. Ewan Thomas MacLeod: Writing – review & editing, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation. Susan Christina Welburn: Writing – review & editing, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Declaration of competing interest

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability

No data was used for the research described in the article.
==== Refs
References

1 De Koning P.H. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history Tropi. Med. Infect. Disease 5 1 2020 14 10.3390/tropicalmed5010014
2 Richards S. Morrison L.J. Torr S.J. Barrett M.P. Manangwa O. Mramba F. Auty H. Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis Trends Parasitol. 37 9 2021 831 843 10.1016/j.pt.2021.04.007 33962879
3 Barrett M.P. Veterinary link to drug resistance in human African trypanosomiasis? Lancet 358 9282 2001 603 604 10.1016/S0140-6736(01)05817-2 11530144
4 Franco J.R. Cecchi G. Paone M. Diarra A. Grout L. Kadima Ebeja A. …Argaw D. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020 PLoS Negl. Trop. Dis. 16 1 2022 e0010047 10.1371/journal.pntd.0010047
5 WHO Benin, Uganda and Rwanda Eliminate Human African Trypanosomiasis as a Public Health Problem Retrieved July 27, 2023, from https://www.who.int/news/item/24-05-2022-benin--uganda-and-rwanda-eliminate-human-african-trypanosomiasis-as-a-public-health-problem 2022
6 Baker N. Glover L. Munday J.C. Andres D.A. Barrett M.P. de Koning H.P. Horn D. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes Proc. Natl. Acad. Sci. USA 109 27 2012 10996 11001 10.1073/pnas.1202885109 22711816
7 Kulohoma B.W. Wamwenje S.A.O. Wangwe I.I. Masila N. Mirieri C.K. Wambua L. Prevalence of trypanosomes associated with drug resistance in Shimba Hills, Kwale County, Kenya BMC Res. Note. 13 1 2020 234 10.1186/s13104-020-05077-3
8 Simo G. Magang E.M.K. Mewamba E.M. Farikou O. Kamga R.M.N. Tume C. …Ravel S. Molecular identification of diminazene aceturate resistant trypanosomes in tsetse flies from Yoko in the Centre region of Cameroon and its epidemiological implications Parasit. Epidemiol. Control 9 2020 10.1016/j.parepi.2020.e00135
9 Welburn S.C. Maudlin I. Simarro P.P. Controlling sleeping sickness - a review Parasitology 136 14 2009 1943 1949 10.1017/S0031182009006416 19691861
10 Gibbs E.P.J. The evolution of one health: a decade of progress and challenges for the future Vet. Rec. 174 4 2014 85 91 10.1136/vr.g143 24464377
11 Laing G. A year of one health and neglected tropical diseases Int. Health 15 5 2023 477 479 10.1093/inthealth/ihad043 37337913
12 Laing G. Vigilato M.A.N. Cleaveland S. Thumbi S.M. Blumberg L. Salahuddin N. …Harrison W. One health for neglected tropical diseases Trans. R. Soc. Trop. Med. Hyg. 115 2 2021 182 184 10.1093/trstmh/traa117 33169163
13 Okello A.L. Gibbs E.P.J. Vandersmissen A. Welburn S.C. One health and the neglected zoonoses: turning rhetoric into reality Vet. Rec. 169 11 2011 281 285 10.1136/vr.d5378 21908565
14 Kasozi K.I. Mujinya Regan Bogere Paul Ekou Justine Zirintunda Gerald Ahimbisibwe Salaviriuse …Welburn Susan Christina Pandemic panic and anxiety in developing countries. Embracing one health offers practical strategies in management of COVID-19 for Africa Pan Afr. Med. J. 35 2 2020 3 10.11604/pamj.supp.2020.35.2.22637
15 Cleaveland S. Lankester F. Townsend S. Lembo T. Hampson K. Rabies control and elimination: a test case for one health Vet. Rec. 175 8 2014 188 193 10.1136/vr.g4996 25172649
16 Nel L.H. Discrepancies in data reporting for rabies, Africa Emerg. Infect. Dis. 19 4 2013 529 533 10.3201/eid1904.120185 23628197
17 Vigilato M.A.N. Clavijo A. Knobl T. Silva H.M.T. Cosivi O. Schneider M.C. …Espinal M.A. Progress towards eliminating canine rabies: policies and perspectives from Latin America and the Caribbean Philos. Trans. R. Soc. B 368 1623 2013 20120143 10.1098/rstb.2012.0143
18 Lefrançois T. Malvy D. Atlani-Duault L. Benamouzig D. Druais P.-L. Yazdanpanah Y. …Lina B. After 2 years of the COVID-19 pandemic, translating one health into action is urgent Lancet 401 10378 2023 789 794 10.1016/S0140-6736(22)01840-2 36302392
19 Leifels M. Khalilur Rahman O. Sam I.-C. Cheng D. Chua F.J.D. Nainani D. …Chan Y.F. The one health perspective to improve environmental surveillance of zoonotic viruses: lessons from COVID-19 and outlook beyond ISME Communicat. 2 1 2022 107 10.1038/s43705-022-00191-8
20 Ruckert A. Zinszer K. Zarowsky C. Labonté R. Carabin H. What role for one health in the COVID-19 pandemic? Can. J. Public Health 111 5 2020 641 644 10.17269/s41997-020-00409-z 32909226
21 Tedros Adhanom WHO Director-General's Remarks at the Press Conference with President of the European COUNCIL to Discuss the Proposal for an International Pandemic Treaty Retrieved March 30, 2021, from https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-member-state-briefing-on-the-report-of-the-international-team-studying-the-origins-of-sars-cov-2 2021
22 Banda G. Wangwe S. Mackintosh M. Making medicines in Africa: An historical political economy overview Making Medicines in Africa 2016 Palgrave Macmillan UK London 7 24 10.1007/978-1-137-54647-0_2
23 Ming A. Puddle J. Wilson H. Antimicrobial Resistance The Role of Regulation Retrieved January 24, 2024, from https://www.ucl.ac.uk/global-governance/sites/global-governance/files/antimicriobial_resistance_the_role_of_regulation_final_draft_report_mb.pdf 2019
24 O’Daniel M. Rosenstein A.H. Professional Communication and Team Collaboration 2008 An Evidence-Based Handbook for Nurses Patient Safety and Quality
25 Di Girolamo N. Meursinge Reynders R. Deficiencies of effectiveness of intervention studies in veterinary medicine: a cross-sectional survey of ten leading veterinary and medical journals PeerJ 4 2016 e1649 10.7717/peerj.1649
26 Butala C.B. Cave R.N.R. Fyfe J. Coleman P.G. Yang G.-J. Welburn S.C. Impact of COVID-19 on the neglected tropical diseases: a scoping review Infect. Dis. Poverty 13 1 2024 55 10.1186/s40249-024-01223-2 39075616
27 Okello A.L. Welburn S.C. The importance of veterinary policy in preventing the emergence and re-emergence of zoonotic disease: examining the case of human African trypanosomiasis in Uganda Front. Public Health 2 2014 218 10.3389/fpubh.2014.00218 25405148
28 Franco J.R. Priotto G. Paone M. Cecchi G. Ebeja A.K. Simarro P.P. …Argaw D.D. The elimination of human African trypanosomiasis: monitoring progress towards the 2021–2030 WHO road map targets PLoS Negl. Trop. Dis. 18 4 2024 1 22 10.1371/journal.pntd.0012111
29 Pfarr K.M. Krome A.K. Al-Obaidi I. Batchelor H. Vaillant M. Hoerauf A. …Kuesel A.C. The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration Parasit. Vectors 16 1 2023 82 10.1186/s13071-022-05581-4 36859332
30 FAO Expert consultation on the sustainable management of parasites in livestock challenged by the global emergence of resistance Part 2: African Animal Trypanosomosis and Drug Resistance – A Challenge to Progressive, Sustainable Disease Control 2022 FAO Rome, Italy 48 10.4060/cc2988en Retrieved from
31 Mulenga G.M. Henning L. Chilongo K. Mubamba C. Namangala B. Gummow B. Insights into the Control and Management of Human and Bovine African Trypanosomiasis in Zambia between 2009 and 2019 — A Review 2019
32 Selby R. Bardosh K. Picozzi K. Waiswa C. Welburn S.C. Cattle movements and trypanosomes: restocking efforts and the spread of Trypanosoma brucei rhodesiense sleeping sickness in post-conflict Uganda Parasit. Vectors 2013 10.1186/1756-3305-6-281
33 Anderson R.M. Cano J. Hollingsworth T.D. Deribe-Kassaye K. Zouré H.G.M. Kello A.B. …Vegvari C. Responding to the cuts in UK AID to neglected tropical diseases control programmes in Africa Trans. R. Soc. Trop. Med. Hyg. 117 3 2023 237 239 10.1093/trstmh/trac109 36416069
34 Engels D. Zhou X.N. Neglected tropical diseases: an effective global response to local poverty-related disease priorities Infect. Dis. Poverty 2020 10.1186/s40249-020-0630-9
35 WHO Funding Crisis Threatens Africa's Fight Against Neglected Tropical Diseases Retrieved January 25, 2024, from https://www.afro.who.int/news/funding-crisis-threatens-africas-fight-against-neglected-tropical-diseases 2023
36 Ainsworth C. Tropical diseases move north Nature 2023 10.1038/d41586-023-03476-7
37 Kennedy C.R.M. de Bruin Y.B. Lequarré A.-S. Ackerman R.T. Luster J. Tsang T.M. …Pilch R. One health security lessons from a year-long webinar series on international COVID-19 response One Health Outlook 4 1 2022 15 10.1186/s42522-022-00071-0 36209267
38 Okello A. Vandersmissen A. Welburn S.C. One health into action: Integrating global health governance with national priorities in a globalized world Zinsstag J. Schelling E. Whittaker M. Tanner M. Waltner-Toews D. One Health: The Theory and Practice of Integrated Health Approaches 2020 CABI Publishing Edinburgh 283 303 10.1079/9781789242577.0394
39 Mbonye A.K. Sekamatte M. Disease outbreaks and reporting in Uganda Lancet 2018 10.1016/S0140-6736(18)32414-0
40 Waiswa C. Azuba R. Makeba J. Waiswa I.C. Wangoola R.M. Experiences of the one-health approach by the Uganda trypanosomiasis control council and its secretariat in the control of zoonotic sleeping sickness in Uganda Parasit. Epidemiol. Control 11 2020 e00185 10.1016/j.parepi.2020.e00185
41 Bakiika H. Obuku E.A. Bukirwa J. Nakiire L. Robert A. Nabatanzi M. …Lamorde M. Contribution of the one health approach to strengthening health security in Uganda: a case study BMC Public Health 23 1 2023 1498 10.1186/s12889-023-15670-3 37550671
42 Global Initiative for Food Systems Leadership Catalog of One Health Activities and Programs 2011 University of Minnesota Retrieved from http://www.foodssystemsleadership.org
43 University of Edinburgh Award for Sleeping Sickness Campaign Retrieved January 25, 2024, from https://www.ed.ac.uk/unpublished/global-health/news-events/news-archive/2013-news/award-sleeping-sickness-campaig 2016
44 Okello A.L. Bardosh K. Smith J. Welburn S.C. One health : past successes and future challenges in three African contexts PLoS Negl. Trop. Dis. 8 5 2014 1 7 10.1371/journal.pntd.0002884
45 Maffioli E.M. Montás M.C. Anyakora C. Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries J. Glob. Health 14 2024 03029 10.7189/jogh.14.03029 38843042
46 Buckley G.J. Gostin L.O. Countering the problem of falsified and substandard drugs Gostin L.O. Buckley G.J. Countering the Problem of Falsified and Substandard Drugs 2013 National Academies Press Washington, D.C. 10.17226/18272
47 Tekle T. Terefe G. Cherenet T. Ashenafi H. Akoda K.G. Teko-Agbo A. …Delespaux V. Aberrant use and poor quality of trypanocides: a risk for drug resistance in south western Ethiopia BMC Vet. Res. 14 1 2018 4 10.1186/s12917-017-1327-6 29304792
48 Kasozi K.I. MacLeod E.T. Sones K.R. Welburn S.C. Trypanocide usage in the cattle belt of southwestern Uganda Front. Microbiol. 14 1 2023 1296522 10.3389/fmicb.2023.1296522 38169897
49 WHO OHHLEP Inventory of One HEALTH Tools and Resources Retrieved January 25, 2024, from https://www.who.int/publications/m/item/ohhlep-inventory-of-one-health-tools 2023
50 WHO Zero draft of the WHO CA+ for the Consideration of the Intergovernmental Negotiating Body at its Fourth Meeting Retrieved from https://apps.who.int/gb/inb/pdf_files/inb4/A_INB4_3-en.pdf 2023
51 Butchard P. Balogun B. What is the proposed WHO Pandemic Preparedness Treaty? Retrieved January 17, 2024, from https://researchbriefings.files.parliament.uk/documents/CBP-9550/CBP-9550.pdf 2023
52 The White House National COVID-19 Preparedness Plan Retrieved January 25, 2024, from https://www.whitehouse.gov/wp-content/uploads/2022/03/NAT-COVID-19-PREPAREDNESS-PLAN.pdf 2022
53 Roozenbeek J. Schneider C.R. Dryhurst S. Kerr J. Freeman A.L.J. Recchia G. …van der Linden S. Susceptibility to misinformation about COVID-19 around the world R. Soc. Open Sci. 7 10 2020 201199 10.1098/rsos.201199
54 Sagan A. Webb E. McKee M. Greer S.L. Karanikolos M. Williams G.A. …Figueras J. Health Systems Resilience during COVID-19. Health Systems Resilience during COVID-19: Lessons for Building Back Better 2021 European Observatory on Health Systems and Policies Copenhagen, Denmark Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK590200/
55 Terry K. Yang F. Yao Q. Liu C. The role of social media in public health crises caused by infectious disease: a scoping review BMJ Glob. Health 8 12 2023 e013515 10.1136/bmjgh-2023-013515
56 Wallace L.J. Agyepong I. Baral S. Barua D. Das M. Huque R. …Elsey H. The role of the private sector in the COVID-19 pandemic: experiences from four health systems Front. Public Health 10 2022 878225 10.3389/fpubh.2022.878225
57 GALVmed Funding for Tryps Phase 3 approved Retrieved November 1, 2021, from https://www.galvmed.org/news/tryps-phase-3-funding-approved/ 2018
58 GALVmed New partnership working on solutions to combat African animal trypanosomiasis Retrieved November 1, 2023, from https://www.galvmed.org/news/new-partnership-working-on-solutions-to-combat-african-animal-trypanosomiasis/ 2023
